At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 398 enrolled
Drug / intervention
Cemiplimab +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
In Brief
A Phase 1 clinical trial evaluating Cemiplimab, Hypofractionated radiotherapy, and 6 other interventions for Advanced Cancer and Advanced Malignancies. Completed, enrolled 398 participants across 47 sites in 3 countries.
Detailed Summary
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer, Advanced Malignancies
CountriesAustralia, Spain, United States
CollaboratorsSanofi
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedMar 2015
Primary CompletionNov 2019
TodayJul 2026
First PostedMar 9, 2015
Enrollment StartFeb 2, 2015
Primary CompletionNov 18, 2019
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.3 years ago
Interventions
Cemiplimabdrug
Hypofractionated radiotherapyradiation
Cyclophosphamidedrug
Docetaxeldrug
Carboplatindrug
GM-CSFdrug
Paclitaxeldrug
Pemetrexeddrug